


PRODUCT INFORMATION



Zoledronic Acid (hydrate)

Item No. 14984

CAS Registry No.: 165800-06-6
Formal Name: P,P'-[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-phosphonic acid, monohydrate
MF: C₅H₁₀N₂O₇P₂ • H₂O
FW: 290.1
Purity: ≥95%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Zoledronic acid (hydrate) is supplied as a crystalline solid. Aqueous solutions of zoledronic acid (hydrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of zoledronic acid (hydrate) in PBS (pH 7.2) is approximately 1.6 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Zoledronic acid is a third-generation heterocyclic nitrogen-containing bisphosphonate that inhibits the prenylation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption.¹ It has a high affinity for hydroxyapatite ($K_i = 3.47 \mu\text{M}$) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis.^{1,2} At μM concentrations, zoledronic acid demonstrates antitumor effects *in vitro* against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis.¹ Zoledronic acid has been used in the treatment of osteoporosis, Paget's disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrate-resistant prostate cancer.^{1,3-6}

References

1. Li, E.C. and David, L.E. Zoledronic acid: A new parenteral bisphosphonate. *Clin. Ther.* **25(11)**, 2669-2708 (2003).
2. Nancollas, G.H., Tang, R., Phipps, R.J., *et al.* Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. *Bone* **38(5)**, 617-627 (2006).
3. R  kel, A., Boucher, A., and Ste-Marie, L.G. Role of zoledronic acid in the prevention and treatment of osteoporosis. *Clin. Interv. Aging* **6**, 89-99 (2011).
4. El-Amm, J., Freeman, A., Patel, N., *et al.* Bone-targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigms. *Prostate Cancer* **2013**, 1-10 (2013).
5. Major, P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. *Oncologist* **7(6)**, 481-491 (2002).
6. Michou, L. and Brown, J.P. Emerging strategies and therapies for treatment of Paget's disease of bone. *Drug Des. Devel. Ther.* **5**, 225-239 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 • USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM